Condition category
Signs and Symptoms
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Frailty, when the word is used in a medical sense, refers to a condition that is common among older adults and involves a reduced ability to withstand "external stressors" (such as infection or surgery) compared with less frail older adults. We know that frailty is associated with aging (but not inevitable), yet we don't fully understand why some older adults develop it more rapidly than others. There are a number of different ways of assessing frailty, with one of the most commonly used and studied methods being the Fried Frailty Criteria. According to these, an individual is considered frail if they score three or more out of five on tests of weight loss, weak grip strength, slow gait speed, reduced physical activity and self-reported exhaustion (a score of one or two is designated "pre-frail", while a score of zero is "robust"). More recent research has been looking at various blood-tests that are associated with frailty and in the future, may provide a simpler means to identify and assess the condition, either alone or in combination.

Frailty is an issue of significant concern, since being frailer has been shown to increase an individual's risk of falling, being admitted to hospital and even death. For this reason, frailty is increasingly used to identify those most in need of support among our aging population. However, this alone is insufficient to manage the increased demands on the health and social services of a growing frail older population. Thankfully, a number of studies have shown that it may be possible to reverse frailty and the most effective treatment seems to be a combination of resistance exercise (weights or resistance bands) and protein supplementation.

Many of these studies have been carried out in settings that are unrealistic to reproduce in practice, with prolonged interventions facilitated by large research teams. What has not been shown is that the same benefit can be achieved through community-based group exercise programs delivered by people without medical expertise. If it could be demonstrated, then this could provide the foundation to encourage widespread participation in resistance exercise for frail older adults living in the community.

Who can participate?
People aged 65 or older who have a diagnosis of frailty

What does the study involve?
Our study involves the development of a new exercise and nutritional intervention by a group of experts in various related fields (Geriatric Medicine, Exercise Physiology, Physiotherapy, General Practice), specifically designed to be suitable and safe for people with a range of levels of frailty, followed by its implementation in a clinical trial. The program itself is eight weeks long and involves three one-hour classes per week in a local fitness centre, led by a staff member with experience in delivering exercise training to older adults. Participants will be asked to attend at least two of these three classes each week. A program logbook has been developed to give clear instructions to both instructors and participants to follow. Each class will involve a combination of aerobic, resistance, balance and flexibility work and requires limited equipment (sets of resistance bands and a chair for each participant). A commercially-available protein-supplemented milk product will also be provided for the duration of the study, of which 250ml is to be consumed twice daily. Through this intervention, we aim to demonstrate the beneficial effect of exercise and protein supplementation on frailty in a “real world” setting.

What are the possible benefits and risks of participating?
The benefits of the study include:
1. Social interaction
2. Improvement in frailty status, strength, mobility, mood (potentially)

The risks of the study include:
1. Transient muscle/joint soreness (mild to moderate)
2. Transient fatigue
3. Fall and associated injury (this risk will be minimized as much as possible)
4. Precipitation of cardiovascular event in individuals with known severe cardiovascular disease or several risk factors for cardiovascular disease (while still estimated to be very low risk)

Where is the study run from?
University Hospital Waterford (Ireland)

When is the study starting and how long is it expected to run for?
July 2018 to July 2020

Who is funding the study?
Royal College of Surgeons in Ireland (Ireland) and Glanbia plc (Ireland)

Who is the main contact?
Dr Pádraig Bambrick

Trial website

Contact information



Primary contact

Dr Pádraig Bambrick


Contact details

Department of Geriatric Medicine
University Hospital Waterford
Dunmore Road
X91 ER8E

Additional identifiers

EudraCT number

Nil known number

Nil known

Protocol/serial number

Nil known

Study information

Scientific title

The effect of a standardised exercise and nutritional intervention on clinical and biochemical markers of frailty in older adults



Study hypothesis

That a novel exercise and nutritional intervention, developed by expert consensus to be feasible for delivery to groups of frail older adults in a community-setting by non-medical professionals, can improve clinical and biochemical markers of frailty

Ethics approval

1. Approved 07/11/2018, University Hospital Waterford Research Ethics Committee (Dunmore Rd, Waterford, Ireland X91 ER8E; +353 051842026)
2. Approved 15/11/2018, Waterford Institute of Technology (Cork Rd, Waterford, Ireland X91 K0EK; +353 051302000;, ref: WIT2018REC0002

Study design

Single-centre non-randomised controlled before-and-after intervention trial

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet




The intervention is an eight-week program of multi-component resistance, aerobic, balance, and flexibility) exercise classes, combined with protein supplementation in the form of commercially available protein supplemented milk (Avonmore Protein Milk) at a dose of 250ml twice daily.

Participants are assessed at baseline, then continue with eight weeks of "regular activity" where no specific advice is given. They are assessed again at this point and then commence the eight-week program. They have the final assessment once they finish the program, at approximately 16 weeks. There is no further follow-up after this point

Intervention type



Drug names

Primary outcome measure

Frailty assessed by Fried frailty criteria comprised of identification of weak grip strength, slow gait speed, excessive weight loss, exhaustion and reduced activity based on pre-determined thresholds at baseline, 8 and 16 weeks

Secondary outcome measures

1. Falls risk as assessed by the Timed Up & Go (TUG) test at baseline, 8 and 16 weeks
2. Functional leg strength assessed by the 30-second sit-to-stand (30STS) test at baseline, 8 and 16 weeks
3. Frailty assessed by Electronic frailty Index (eFI) at baseline, 8 and 16 weeks
4. Body composition assessed by the Bio-electrical Impedance Analysis (BIA) using BodyStat Quadscan 4000 at baseline, 8 and 16 weeks
5. Arterial stiffness assessed by Carotid-femoral Pulse Wave Velocity (cfPWV) using Complior Analyse device & software at baseline, 8 and 16 weeks
6. Cognitive impairment assessed by Montreal Cognitive Assessment (MoCA) by face-to-face interview at baseline, 8 and 16 weeks
7. Depression assessed by the Geriatric Depression Scale Short Form (GDS-SF) by face-to-face interview at baseline, 8 and 16 weeks
8. Quality of life assessed by the CASP-19 quality of life scale by face-to-face interview at baseline, 8 and 16 weeks
9. Pain as assessed by the Pain Numerical Rating Scale (PNRS) by face-to-face interview at baseline, 8 and 16 weeks
10. Frailty assessed through biochemical markers of frailty in serum samples analysed using MagPix Luminex system (CRP, IL-6, IL-8, IL-10, TNF-alpha and IFN-gamma) and standalone ELISA (Cystatin-C) at baseline, 8 and 16 weeks

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Aged ≥65 years
2. Clinical Frailty Scale (CFS) score of ≥5 as assessed by the multidisciplinary team of a geriatric medicine outpatient clinic

Participant type


Age group




Target number of participants


Total final enrolment


Participant exclusion criteria

1. Unable to mobilise without the assistance of another person
2. Severe cognitive or sensory impairment that would prevent participation in the intervention, even despite reasonable supports
2. Participation in any research that could impact on the outcome of this study
3. Documented milk-allergy

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

University Hospital Waterford
Dunmore Road
X91 ER8E

Sponsor information


Royal College of Surgeons in Ireland

Sponsor details

123 St. Stephen's Green
Dublin 2
D02 YN77

Sponsor type




Funder type


Funder name

Royal College of Surgeons in Ireland

Alternative name(s)

Coláiste Ríoga na Máinleá in Éirinn, RCSI

Funding Body Type

private sector organisation

Funding Body Subtype

Universities (academic only)



Funder name

Glanbia plc

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

This work forms the basis of a two-year MD, with thesis submission planned for July 2020.
It is also hoped that a number of publications will arise from this project, including a protocol paper (in process), methodology paper (in process) and results paper.

IPD Sharing statement:
The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication

Intention to publish date


Participant level data


Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes

03/07/2020: The participant information sheet has been uploaded. 19/06/2020: Internal review. 13/02/2020: Trial’s existence confirmed by University Hospital Waterford Research Ethics Committee.